Shares of Solar Pharmaceutical Industries Ltd, India’s largest drugmaker, noticed its shares fall nearly 2% on Monday, 16 June, after the US Meals and Drug Administration (USFDA) issued eight observations for its Halol manufacturing facility in Gujarat.
Solar Pharma said in a regulatory submitting that the USFDA carried out a Good Manufacturing Practices (GMP) examination at its Halol facility from 2 June to 13 June 2025.
The inspection concluded with the issuance of a Kind 483 with eight observations indicating potential procedural or documentation errors that required corrective motion.
The Halol manufacturing unit, one of many firm’s important manufacturing websites, has beforehand acquired regulatory inspection and has been on import alert since Could 2022, when a warning letter was issued prohibiting exports to the US.
Solar Pharma claimed that it’s going to deal with the observations and implement the mandatory corrective steps.
The USFDA issued an import discover on the plant following the inspection in April-Could 2022, and it was later classed as OAI (Official Motion Indicated) in August 2022. Throughout that examination, the USFDA issued ten Kind 483 observations. The observations targeted on manufacturing methods, services and tools, high quality management procedures, and lab management methods. The plant has been classed as OAI since March 2020.
Even throughout the December 2019 go to, the US FDA made eight Kind 483 observations. The positioning has beforehand skilled various poor regulatory outcomes. As well as, it acquired a warning discover in 2015.
At 12:45 pm, the shares of Solar Pharma have been buying and selling 0.21% decrease at Rs 1,686.10 on NSE.
Uncover the subsequent huge funding! Unicorn Indicators’ IPO screener helps you establish promising preliminary public choices. Obtain Unicorn Indicators and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
